# Vertex finishes zimislecel manufacturing analysis and resumes dosing

Canonical page: https://technooptimist.io/stories/vertex-finishes-zimislecel-manufacturing-analysis-and-resumes-dosing-cc202f55
Date: 4 May 2026
About: [Vertex Pharmaceuticals](https://technooptimist.io/companies/vertex-pharmaceuticals.md) · [Zimislecel](https://technooptimist.io/biotech/zimislecel.md)
Original source: https://investors.vrtx.com/news-releases/news-release-details/vertex-reports-first-quarter-2026-financial-results

Vertex said in its first-quarter 2026 results that it had completed the internal manufacturing analysis for the Phase 1/2/3 study of zimislecel, its stem-cell islet therapy for type 1 diabetes, and had resumed dosing. The company says multiple patients have been treated since dosing restarted.

## Key facts

- The release says Vertex completed the internal manufacturing analysis and resumed dosing, but does not say on what date dosing restarted.
- Vertex expects to give updated timelines for completing the study later in 2026.
- The release gives no new date for regulatory submissions.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.